Aratana Therapeutics Regains Rights to AT-004

The Company announced it has regained manufacturing and commercial rights for AT-004, a monoclonal antibody that received a full product license from the U.S. Department of Agriculture (USDA) on January 2, 2015 as an aid in the treatment of canine B-cell lymphoma.